Table 2:
Table of secondary endpoint results
| No TVS | TVS | p-value | |
|---|---|---|---|
| 6-minute walk test, feet | |||
| 2-4 months | |||
| Median (Q1, Q3) | 929 (720, 1132) | 890 (600, 1120) | n.s. |
| 4-6 months | |||
| Median (Q1, Q3) | 999 (702, 1211) | 1005.0 (784, 1174) | 0.917 |
| KCCQ (6 month) | |||
| Physical Limitation | |||
| Median (Q1, Q3) | 66.7 (50.0, 83.3) | 85.4 (56.3, 91.7) | n.s. |
| Symptom Frequency | |||
| Median (Q1, Q3) | 87.5 (66.7, 100.0) | 87.5 (70.8, 95.8) | n.s. |
| Quality of Life | |||
| Median (Q1, Q3) | 62.5 (43.8, 81.3) | 75.0 (56.3, 87.5) | n.s. |
| Social Limitation | |||
| Median (Q1, Q3) | 75.0 (58.3, 100.0) | 83.3 (58.3, 100.0) | n.s. |
| Summary | |||
| Median (Q1, Q3) | 71.6 (47.7, 82.0) | 78.4 (62.8, 93.2) | 0.654 |
| Hospital length of stay days, median (Q1, Q3) | 15.5 (13.0, 23.0) | 23.0 (17.0, 31.0) | 0.103 |
| ICU length of stay days, median (Q1, Q3) | 6.5 (4.0, 9.0) | 5.5 (4.0, 11.0) | 0.917 |
| Total days of inotropic support, median (Q1, Q3) | 7 (6, 14) | 7 (5, 11) | n.s. |
| Total days of pulmonary vasodilator support, median (Q1, Q3) | 3 (2, 5.3) | 3 (1, 4) | n.s. |
| Total days of RVAD support in those requiring RVAD, median (Q1, Q3) | 6 (5, 8) | 3 (2, 5) | n.s. |
| Number of readmissions, N(%) | 0.654 | ||
| 1 | 6 (21.4%) | 10 (31.3%) | |
| 2 | 2 (7.1%) | 0 (0.0%) | |
| 3 | 2 (7.1%) | 4 (12.5%) | |
| 4 | 0 (0.0%) | 1 (3.1%) | |
| Number of readmissions for right heart failure, N (%) | |||
| 1 | 0 (0.0%) | 4 (12.5%) | n.s. |
| NYHA Class, N (%) | |||
| 1 Month | n.s. | ||
| Class 1 | 1 (4.5) | 0 (0.00) | |
| Class 2 | 10 (45.5) | 11 (47.8) | |
| Class 3 | 10 (45.5) | 9 (39.1) | |
| Class 4 | 1 (4.5) | 3 (13.0) | |
| 3 Month | n.s. | ||
| Class 1 | 5 (22.7) | 3 (10.7) | |
| Class 2 | 11 (50.0) | 19 (67.9) | |
| Class 3 | 5 (22.7) | 5 (17.9) | |
| Class 4 | 1 (4.5) | 1 (3.6) | |
| 6 Month | 0.913 | ||
| Class 1 | 7 (35.0) | 6 (25.0) | |
| Class 2 | 11 (55.0) | 14 (58.3) | |
| Class 3 | 2 (10.1) | 4 (16.7) | |
| Post-op labs (6-months) | |||
| Creatinine | |||
| 1-month | |||
| Median (Q1, Q3) | 1.00 (0.90, 1.50) | 1.20 (1.00, 1.40) | n.s. |
| 3-months | |||
| Median (Q1, Q3) | 1.20 (1.00, 1.60) | 1.20 (1.10, 1.60) | n.s. |
| 6-months | |||
| Median (Q1, Q3) | 1.30 (1.00, 1.70) | 1.25 (1.10, 1.50) | n.s. |
| Bilirubin, total | |||
| 1-month | |||
| Median (Q1, Q3) | 0.90 (0.70, 1.40) | 1.05 (0.80, 1.70) | n.s. |
| 3-months | |||
| Median (Q1, Q3) | 1.00 (0.70, 1.10) | 0.90 (0.60, 1.20) | n.s. |
| 6-months | |||
| Median (Q1, Q3) | 0.80 (0.60, 1.10) | 1.00 (0.70, 1.20) | n.s. |
*
n.s. = not significant